Open AccessP1163: OUTCOMES OF HIGH‐RISK LARGE B‐CELL LYMPHOMA TREATED WITH STANDARD OF CARE CHEMOIMMUNOTHERAPY: A NON‐RANDOMIZED COMPARISON TO FRONTLINE CAR‐T CELL THERAPY
Author(s) -
Albanyan O.,
CastanedaPuglianini O.,
Chavez J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847520.82769.e5
Subject(s) - medicine , chemoimmunotherapy , clinical endpoint , interim analysis , oncology , progression free survival , randomized controlled trial , lymphoma , rituximab , chemotherapy